Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma
To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n=31)...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
19 March 2008
|
| In: |
International journal of cancer
Year: 2008, Volume: 122, Issue: 12, Pages: 2871-2875 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.23455 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.23455 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.23455 |
| Author Notes: | Jens Hillengass, Christian M. Zechmann, Andreas Nadler, Dirk Hose, Friedrich W. Cremer, Anna Jauch, Christiane Heiss, Axel Benner, Anthony D. Ho, Claus R. Bartram, Hans-Ulrich Kauczor, Stefan Delorme, Hartmut Goldschmidt and Thomas M. Moehler |
| Summary: | To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n=31) and untreated multiple myeloma (MM) (n = 87) patients. The adverse cytogenetic abnormalities gain of 1q21, deletion 17p13 and deletion 13q14 significantly correlated with at least one DCE-MRI finding (aberrant “focal” microcirculation pattern, increase in median microcirculation parameter Amplitude A or exchange rate constant kep). We conclude that gain of 1q21, deletion 13q14 and deletion 17p13 trigger the angiogenic cascade in MM. Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used. © 2008 Wiley-Liss, Inc. |
|---|---|
| Item Description: | Gesehen am 12.10.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.23455 |